<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540449</url>
  </required_header>
  <id_info>
    <org_study_id>CR002689</org_study_id>
    <secondary_id>TMC278-TIDP6-C209</secondary_id>
    <nct_id>NCT00540449</nct_id>
    <nct_alias>NCT00613639</nct_alias>
  </id_info>
  <brief_title>TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.</brief_title>
  <official_title>A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec Pharmaceuticals, Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec Pharmaceuticals, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278
      given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily,
      when combined with a fixed background regimen consisting of emtricitabine (FTC) + tenofovir
      disoproxil fumarate (TDF), in HIV-1 infected patients who have not yet taken any anti-HIV
      drugs. The following evaluations will be done: antiviral activity, immunologic changes, and
      viral geno-/phenotype evolution, relationship of Pharmacokinetics (PK) and
      PK/Pharmacodynamics, medical resource utilization and treatment adherence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past decade, anti-human immunodeficiency virus (HIV) drugs have been introduced
      sequentially for use in the clinic. Currently, patients are routinely being treated with 3 or
      4 drug combinations including nucleoside/tide analogue reverse transcriptase inhibitors
      (NRTIs/NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors
      (PIs), and/or fusion inhibitors. New potent antiretroviral (ARV) compounds that work in
      people whose HIV-1 virus is resistant to available drugs are urgently needed. This is a Phase
      III, randomized (study medication is assigned by chance), double-blind (neither the study
      physician nor the patient knows the name of the study assigned medication), double-dummy,
      active-controlled trial to compare the effectiveness, safety, and ability to tolerate TMC278
      versus efavirenz (EFV). The study will last for 104 weeks which includes a screening period
      of 4 weeks, a 96-week treatment period, followed by a 4 week follow-up period. Patients will
      be randomly assigned to TMC278 or to efavirenz, either of these treatments will be in
      combination with two other anti-HIV drugs (2 NRTIs: emtricitabine (FTC) + tenofovir (TDF)).
      TDF/FTC will be administered as a fixed dose combination if available. The hypothesis to be
      provided in this study is that the investigational drug TMC278 will perform just like
      efavirenz (EFV) in terms of antiviral effectiveness (i.e., suppressing of the plasma viral
      load to a level &lt; 50 HIV-1 RNA (ribonucleic acid) copies/mL) in ARV-na√Øve HIV-infected
      patients. During the trial, patients' health will be monitored by physical examination,
      interview to assess health and well being, and laboratory testing on blood and urine samples.
      Experimental Group: One tablet of TMC278 25 mg once daily plus one tablet of placebo once
      daily that looks just like efavirenz (EFV) plus tenofovir/emtricitabine; Control Group: One
      tablet of Placebo once daily that looks just like TMC278 plus EFV 600 mg once daily plus
      tenofovir/emtricitabine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies/ml) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Virological response is defined as confirmed plasma viral load less than (&lt;) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load &lt;50 copies/ml).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies/ml) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL&lt;50 copies/ml (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL&gt;=50 copies/ml in the Wk48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL&gt;=50 copies/ml and subjects who had a switch in background regimen that was not permitted by the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies/ml) at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies/ml) at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Observed, &lt;50 Copies/ml) at Last On-Treatment Visit (Post-Week 96).</measure>
    <time_frame>Variable, ranging from 3 months up to maximum 15 months for TMC278 and 12 months for Efavirenz after the 96-week visit</time_frame>
    <description>Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per ml at the last on-treatment visit (post-Week 96).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies/ml) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies/ml) at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)</measure>
    <time_frame>Baseline, Week 48, and Week 96</time_frame>
    <description>Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virologic Failure for the Resistance Determination by Emerging Resistance Associated Mutations: First Available On-Treatment Genotypic Data After Failure</measure>
    <time_frame>Week 96</time_frame>
    <description>Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load &lt;50 copies/mL) and plasma viral load increase of &gt;=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">694</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV-1</condition>
  <condition>Human Immunodeficiency Virus Type 1</condition>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efavirenz 600mg once daily for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC278</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC278 25 mg tablet once daily for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC278</intervention_name>
    <description>25 mg tablet once daily for 96 weeks</description>
    <arm_group_label>TMC278</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600mg once daily for 96 weeks</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with documented HIV-1 infection

          -  Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to
             screening

          -  Patient's HIV-1 plasma viral load at screening is &gt; 5,000 HIV-1 RNA copies/mL (assayed
             by RNA PCR standard specimen procedure)

          -  Patient's virus is sensitive to TDF and FTC

          -  Patient agrees not to start ART (antiretroviral treatment) before the baseline visit

        Exclusion Criteria:

          -  Previous use of ANY ARV drug for ANY length of time

          -  Any documented evidence of NNRTI resistance associated mutations in patient's HIV

          -  Category C AIDS defining illness, except: stable Kaposi Sarcoma, wasting syndrome if
             not progressive

          -  Pneumocystis carinii pneumonia (PCP) that is considered not cured

          -  Active TB

          -  Allergy or hypersensitivity to study or background ARTs

          -  Specific grade 3 or 4 toxicity

          -  Kidney impairment: calculated creatinine clearance &lt;50 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec Pharmaceuticals Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec Pharmaceutical Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guernica</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surry Hills</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nova Iguacu</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hvidovre N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad De Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portimao</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban N/A</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houghton, Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria N/A</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>G√∂teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malm√∂</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Uganda</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <results_first_submitted>June 14, 2011</results_first_submitted>
  <results_first_submitted_qc>June 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2011</results_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMC278-C209</keyword>
  <keyword>Antiretroviral</keyword>
  <keyword>Non-nucleoside reverse transcriptase inhibitor</keyword>
  <keyword>HIV-1</keyword>
  <keyword>AIDS</keyword>
  <keyword>TMC278-TiDP6-C209</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One hundred and twelve sites in 21 countries randomized participants. In total, 694 participants were randomized: four participants did not start treatment and 690 participants started treatment (346 in the TMC278 group and 344 in the efavirenz [control ] group).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>TMC278</title>
          <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Efavirenz</title>
          <description>600 mg once daily for 96 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="346"/>
                <participants group_id="P2" count="344"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Ineligible To Continue The Trial</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliant</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Reached A Virologic Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population included intent to treat (ITT) population defined as all randomized participants who received at least one dose of the study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>TMC278</title>
          <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Efavirenz</title>
          <description>600 mg once daily for 96 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="346"/>
            <count group_id="B2" value="344"/>
            <count group_id="B3" value="690"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="9.68"/>
                    <measurement group_id="B2" value="36.7" spread="9.51"/>
                    <measurement group_id="B3" value="36.8" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region Enroll</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>USA, Canada, Europe, Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies/ml) at Week 48</title>
        <description>Virological response is defined as confirmed plasma viral load less than (&lt;) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load &lt;50 copies/ml).</description>
        <time_frame>Week 48</time_frame>
        <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies/ml) at Week 48</title>
          <description>Virological response is defined as confirmed plasma viral load less than (&lt;) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load &lt;50 copies/ml).</description>
          <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to Adverse Event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to other reason than AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a response rate of 75% at 48 weeks for both treatment groups, 340 subjects were needed per treatment (TMC278 or EFV) to establish non-inferiority of TMC278 versus EFV with a maximum allowable difference of 12% and a 1-sided significance level of 2.5%, to yield 95% power.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significance level was set at 2.5% (one-sided). No adjustment of p-value for multiple comparisons, since there was only single comparison for the primary endpoint.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm as factor and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
            <estimate_desc>Difference in proportion responders was estimated through the logistic regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies/ml) at Week 48</title>
        <description>The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL&lt;50 copies/ml (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL&gt;=50 copies/ml in the Wk48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL&gt;=50 copies/ml and subjects who had a switch in background regimen that was not permitted by the protocol.</description>
        <time_frame>Week 48</time_frame>
        <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies/ml) at Week 48</title>
          <description>The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL&lt;50 copies/ml (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL&gt;=50 copies/ml in the Wk48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL&gt;=50 copies/ml and subjects who had a switch in background regimen that was not permitted by the protocol.</description>
          <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virologic Response HIV RNA &lt;50 copies/mL at Wk 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Viral Load Data in 48 week window</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm as factor and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>Difference in proportion responders was estimated through the logistic regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies/ml) at Week 96</title>
        <time_frame>Week 96</time_frame>
        <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies/ml) at Week 96</title>
          <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to other reason than AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>0.0055</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm as factor and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>Difference in proportion responders was estimated through the logistic regression model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies/ml) at Week 96</title>
        <time_frame>Week 96</time_frame>
        <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies/ml) at Week 96</title>
          <population>The Intent-to-Treat analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virologic Response, &lt;50 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virologic failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No viral load data in the 96 week window</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% 2-sided confidence interval of the difference in proportions (TMC278 ‚Äì EFV) exceeds -12%, non-inferiority of TMC278 versus EFV can be concluded.</non_inferiority_desc>
            <p_value>0.0013</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model included treatment arm as factor and baseline (log10) viral load as covariate.</method_desc>
            <param_type>Difference in proportion of response</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Observed, &lt;50 Copies/ml) at Last On-Treatment Visit (Post-Week 96).</title>
        <description>Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per ml at the last on-treatment visit (post-Week 96).</description>
        <time_frame>Variable, ranging from 3 months up to maximum 15 months for TMC278 and 12 months for Efavirenz after the 96-week visit</time_frame>
        <population>Participants with at least 1 Post-Week 96 visit were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Observed, &lt;50 Copies/ml) at Last On-Treatment Visit (Post-Week 96).</title>
          <description>Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per ml at the last on-treatment visit (post-Week 96).</description>
          <population>Participants with at least 1 Post-Week 96 visit were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies/ml) at Week 48</title>
        <time_frame>Week 48</time_frame>
        <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies/ml) at Week 48</title>
          <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies/ml) at Week 96</title>
        <time_frame>Week 96</time_frame>
        <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies/ml) at Week 96</title>
          <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)</title>
        <description>Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.</description>
        <time_frame>Baseline, Week 48, and Week 96</time_frame>
        <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)</title>
          <description>Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.</description>
          <population>The ITT analysis set was considered the primary efficacy analysis set.</population>
          <units>cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absolute cell count, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.5" spread="151.7"/>
                    <measurement group_id="O2" value="181.6" spread="156.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute cell count, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.7" spread="167.1"/>
                    <measurement group_id="O2" value="226.7" spread="188.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative cell count, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="5.8"/>
                    <measurement group_id="O2" value="8.7" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relative cell count, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="7.5"/>
                    <measurement group_id="O2" value="10.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virologic Failure for the Resistance Determination by Emerging Resistance Associated Mutations: First Available On-Treatment Genotypic Data After Failure</title>
        <description>Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load &lt;50 copies/mL) and plasma viral load increase of &gt;=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).</description>
        <time_frame>Week 96</time_frame>
        <population>The ITT analysis set was considered the primary efficacy analysis set. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable (had data) for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC278</title>
            <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz</title>
            <description>600 mg once daily for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virologic Failure for the Resistance Determination by Emerging Resistance Associated Mutations: First Available On-Treatment Genotypic Data After Failure</title>
          <description>Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load &lt;50 copies/mL) and plasma viral load increase of &gt;=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).</description>
          <population>The ITT analysis set was considered the primary efficacy analysis set. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable (had data) for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any RAM from Extended NNRTI RAMs list</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: E138K</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: K101E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: Y181C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: V90I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: V189I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: H221Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: E138Q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NNRTI RAM: K103N</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any RAM from IAS-USA N(t)RTI RAMs list</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N(t)RTI RAM: M184I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N(t)RTI RAM: M184V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N(t)RTI RAM: K065R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N(t)RTI RAM: K219E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N(t)RTI RAM: Y115F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to a maximum of 160 weeks for participants in the TMC278 treatment group and up to 147 weeks for participants in the efavirenz treatment group.</time_frame>
      <desc>Only subjects who had at least one of the TEAEs listed in the Other (non Serious) AE table are included in the Total no. subjects with Non-Serious Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>TMC278</title>
          <description>25 milligram (mg) tablet once daily for 96 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Efavirenz</title>
          <description>600 mg once daily for 96 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Splenic lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroglossal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Meningococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Miller fisher syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bowel preparation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Drug rehabilitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="231" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="268" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Leader</name_or_title>
      <organization>Janssen Infectious Diseases BVBA</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

